Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 1-2/2004

01-11-2004 | Original Paper

Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products

Authors: Reuven Or, Memet Aker, Michael Yechiel Shapira, Igor Resnick, Menachem Bitan, Simcha Samuel, Shimon Slavin

Published in: Seminars in Immunopathology | Issue 1-2/2004

Login to get access

Abstract

Our understanding of the pathophysiology of hematopoietic failure associated syndromes led to the developmental of potentially curative procedures for the treatment of many diseases including Severe aplastic anemia, Fanconi’s anemia, Primary immunodeficiency, Osteopetrosis, and Metabolic diseases.
Although the number of patients that were transplanted for bone marrow deficiency diseases is relatively low as compared to patients with hematological malignancies, the impact on the knowledge of hematopoiesis and transplantation biology is tremendous. Moreover, the patient’s average young age suffering from these diseases further encourage searching for curative approaches.
Lucking a fully MHC matched donor, remained a significant obstacle in stem cell transplantation for non-malignant hematological disorders. Lessons from attempts to cure aplasic anemia with bone marrow transplantation guided us to the improvement of pretransplant conditioning regimens and prevention of graft versus host reactions after transplantation.
Furthermore, in recent years optimization of disease specific protocol have been successfully designed and clinically applied.
Literature
1.
Sanders JE, Whitehead J, Storb R, et al (1986) Bone marrow transplantation experience for children with aplastic anemia. Pediatrics 77:179
2.
Locasciulli A, Van’t Veer L, Bacigalupo A, et al (1990) Treatment with bone marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: a report from the EBMT SAA working party. Bone Marrow Transplant 6:211
3.
Anasetti C, Doney KC, Storb R, et al (1986) Marrow transplantation for severe aplastic anemia. Long term outcome in fifty “untransfused” patients. Ann Intern Med 104:461
4.
Storb R, Doney KC, Thomas ED, et al (1982) Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 59:236
5.
Storb R, Sanders JE, Pepe M, et al (1991) Graft-versus host disease prophylaxis with methotrexate/cyclophosphamide in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. Blood 78:1144
6.
May WS, Sensenbrenner LL, Burns WH, et al (1993) BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant 11:459
7.
Feig SA, Champlin R, Arenson E, et al (1983) Improved survival following bone marrow transplantation for aplastic anemia. Br J hematol 54:509
8.
Chaplin RE, Ho WG, Nimer SD, et al (1990) Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low dose total lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy. Transplantation 49:720
9.
Castro-Malaspina H, Childs B, Laver J, et al (1994) Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA- identical marrow transplantation for severe aplastic anemia. Int J Radiat Oncol Biol Phys 29:847
10.
Deeg HJ, Leisenring W, Storb R, et al (1998) Long term outcome after marrow transplantation for severe aplastic anemia. Blood 91:3637
11.
Sanders JE, Team at SMT (1991) The impact of marrow transplant preparative regimens on subsequent growth and development. Semin Hematol 28:244
12.
Clement-de Boers A, Oostdijk W, Van Weel-Sipman MH, et al (1996) Final height and hormonal function after bone marrow transplantation in children. J Pediatr 129:544
13.
Horstmann M, Stockschlader M, Kruger W, et al (1995) Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Ann Hematol 71:77
14.
Storb R, Etzioni R, Anasetti C, et al (1994) Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 84:941
15.
Slavin S, Nagler A, Naprastek E, et al (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756
16.
Hows JM (1991) Severe aplastic anemia: the patient without an HLA-identical sibling. Br J Haematol 77:1
17.
D’Andrea AD, Grompe M (1997) Molecular biology of Fanconi anemia: implications for diagnosis and therapy. Blood 90:1725
18.
Young NS, Alter BP (1994) Clinical features of Fanconi’s anemia. In: Young NS, Alter BP (eds) Aplastic anemia acquired and inherited. Saunders, Philadelphia, pp 275–309
19.
Butturini A, Gale RP, Verlander PC, et al (1994) Hematologic abnormalities in Fanconi anemia: an international Fanconi anemia registry study. Blood 84:1650
20.
Guardiola P, Socie G, Pasquini R, et al (1998) Allogeneic stem cell transplantation for Fanconi anaemia. Severe Aplastic Anaemia Working Party of the EBMT and EUFAR. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant Suppl 2:S24
21.
Gluckman E, Devergie A, Schaison G, et al (1980) Bone marrow transplantation in Fanconi anaemia. Br J Haematol 45:557
22.
Socie G, Gluckman E, Raynal B, et al (1993) Bone marrow transplantation for Fanconi anemia using low-dose cyclophosphamide/thoracoabdominal irradiation as conditioning regimen: chimerism study by the polymerase chain reaction. Blood 82:2249
23.
Kapelushnik J, Or R, Slavin S, et al (1997) A fludarabine-based protocol for bone marrow transplantation in Fanconi’s anemia. Bone Marrow Transplant 20:1109
24.
O’Reilly RJ, Dupont B, Pahwa S, et al (1997) Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 297:1311
25.
Parkman R (1990) The biology of bone marrow transplantation for severe combined immune deficiency. Adv Immunol 49:381
26.
Buckley RH, Schiff SE, Schiff RI, et al (1999) Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340:508
27.
Fischer A, Griscelli C, Friedrich W, et al (1986) Bone marrow transplantation for immunodeficiencies and osteopetrosis: European Survey, 1968–1985. Lancet II:1080
28.
Bach FH, Albertini RJ, Joo P, et al (1968) Bone marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet II:1364
29.
Parkman R, Rappeport J, Geha R, et al (1978) Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone marrow transplantation. N Engl J Med 198:921
30.
Ozsahin H, Le Deist F, Benkerrou M, et al (1996) Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome for a single center. J Pediatr 129:238
31.
Sly W (1989) Carbonic anhydrase deficiency syndrome: osteopetrosis with renal tubular acidosis and cerebral calcifications. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 2857–2866
32.
Helfrich M, Aronson D, Everts V, et al (1991) Morphologic features of bone in human osteopetrosis. Bone 12:411
33.
Van Hul W, Bollerslev J, Gram J, et al (1997) Localization of a gene for autosomal dominant osteopetrosis (Albers-Schonberg disease) to chromosome 1p2. Am J Hum Genet 61:363
34.
Seiff CA, Chessels JM, Levinsky R (1983) Allogenic bone-marrow transplantation in infantile malignant osteopetrosis. Lancet I:437
35.
Gerritsen EJ, Vossen JM, Loo IH, et al (1994) Autosomal recessive osteopetrosis: variability of findings at diagnosis and during the natural course. Pediatrics 93:247
36.
Horton WA, Schimk RN, Lyama T (1980) Osteopetrosis: further heterogeneity. J Pediatr 97:580
37.
Bollerslev J (1989) Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. Endocr Rev 10:45
38.
39.
Heaney C, Shalev H, Elbedour K, et al (1998) Human autosomal recessive osteopetrosis maps to 11q13, a position predicted by comparative mapping of the murine osteosclerosis (oc) mutation. Hum Mol Genet 7:1407
40.
Abinun M, Newson T, Rowe PW, et al (1990) Importance of neurological assessment before bone marrow transplantation for osteopetrosis. Arch Dis Child 80:273
41.
Ruben JB, Morris RJ, Judisch GF (1990) Chorioretinal degeneration in infantile malignant osteopetrosis. Am J Ophthalmol 110:1
42.
Al-Mefty O, Fox JL, Al-Rodhan N, et al (1988) Optic nerve decompression in osteopetrosis. J Neurosurg 68:80
43.
Eapen M, Davies SM, Ramsay NKC, et al (1998) Hematopoietic stem cell transplantation for infantile osteopetrosis. Bone Marrow Transplant 22:941
44.
Coccia PF, Krivit W, Cervenka J, et al (1980) Successful bone marrow transplantation for infantile malignant osteopetrosis. N Engl J Med 302:701
45.
Key L, Carnes D, Cole S, et al (1984) Treatment of congenital osteopetrosis with high-dose calcitrol. N Engl J Med 310:409
46.
Aarskog D, Asknes L, Haneberg B, et al (1979) Acute response of parathyroid hormone in congenital osteopetrosis. Acta Paediatr Scand Suppl 277:75
47.
Key LL, Ries WL, Rodriguiz RM, et al (1992) Recombinant human interferon gamma therapy for osteopetrosis. J Pediatr 121:119
48.
Li YP, Chen W, Liang Y, et al (1999) Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 23:447
49.
Horwitz EM, Gordon PL, Koo WK, et al (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 99:8932
50.
Hobbs JR, Hugh-Jones K, Barrett AJ, et al (1981) Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet II:709
51.
Peters C, Balthazor M, Shapiro EG, et al (1996) Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 87:4894
52.
Krivit W, Lockman LA, Watkins PA, et al (1995) The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis 18:398
53.
Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al (1995) Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 345:1398
54.
Vellodi A, Young EP, Cooper A, et al (1997) Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 76:92
55.
McKinnis EJ, Sulzbacher S, Rutledge JC, et al (1996) Bone marrow transplantation in Hunter syndrome. J Pediatr 129:145
56.
Malm G, Ringden O, Winiarski J, et al (1996) Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. Bone Marrow Transplant 17:1003
57.
Vellodi A, Cragg H, Winchester B, et al (1995) Allogeneic bone marrow transplantation for fucosidosis. Bone Marrow Transplant 15:153
58.
Ringden O, Groth CG, Erikson A, et al (1995) Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplantation 59:864
59.
Krivit W, Peters C, Shapiro EG (1999) Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 12:167
Metadata
Title
Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products
Authors
Reuven Or
Memet Aker
Michael Yechiel Shapira
Igor Resnick
Menachem Bitan
Simcha Samuel
Shimon Slavin
Publication date
01-11-2004
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 1-2/2004
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-004-0169-z

Other articles of this Issue 1-2/2004

Seminars in Immunopathology 1-2/2004 Go to the issue

Original Paper

Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases

Original Paper

Application of xenogeneic stem cells for induction of transplantation tolerance: present state and future directions

Original Paper

Cord blood transplant: strategy of alternative donor search

Original Paper

Allogeneic stem cell transplantation for the treatment of advanced solid tumors

Original Paper

Stem-cell transplantation for the treatment of advanced solid tumors

Original Paper

Allogeneic stem cell transplantation for treatment of immunodeficiency
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits